S'abonner

Fetal fibronectin as a predictor of preterm birth in patients with symptoms: A multicenter trial - 10/09/11

Doi : 10.1016/S0002-9378(97)70431-9 
Alan M. Peaceman, MD, William W. Andrews, PhD, MD, John M. Thorp, MD,, Suzanne P. Cliver, PhD, A. Lukes, MD, MHS, Jay D. Iams, MD, Laura Coultrip, MD,, Nancy Eriksen, MD, R.Harold Holbrook, MD, John Elliott, MD, Charles Ingardia, MD, Marcello Pietrantoni, MD
Chicago, Illinois, Birmingham, Alabama, Chapel Hill, North Carolina, Columbus, Ohio, Minneapolis, Minnesota, Houston, Texas, Stanford, California, Phoenix, Arizona, Hartford, Connecticut, and Louisville, Kentucky 

Abstract

OBJECTIVE: Our aim was to determine whether the presence of fetal fibronectin in vaginal secretions of patients with symptoms suggestive of preterm labor predicts preterm delivery. STUDY DESIGN: Patients who were examined at the hospital between 24 weeks' and 34 weeks 6 days' gestation with intact membranes, no prior tocolysis, symptoms suggestive of preterm labor, and cervical dilation <3 cm were recruited at 10 sites. Swabs of the posterior fornix were assayed for the presence of fetal fibronectin by monoclonal antibody assay, with a positive result defined as ≥50 ng/ml. Results were not available to the managing physicians. Tocolysis was used when clinically indicated after specimen collection. RESULTS: A total of 763 patients had fetal fibronectin results and pregnancy outcome data available for analysis. Fetal fibronectin was detected in specimens from 150 (20%) patients. Compared with patients who had negative results, patients who had positive results for fetal fibronectin were more likely to be delivered within 7 days (relative risk 25.9 [95% confidence interval 7.8 to 86]), within 14 days (relative risk 20.4 [95% confidence interval 8.0 to 53]), and before 37 completed weeks (relative risk 2.9 [95% confidence interval 2.2 to 3.7]). The negative predictive values for delivery within 7 days, within 14 days, and at <37 weeks were 99.5%, 99.2%, and 84.5%, respectively. When we used multiple logistic regression analysis to control for potential confounding variables among singleton pregnancies, only the presence of fetal fibronectin (odds ratio 48.8, 95% confidence interval 7.4 to 320), prior preterm birth (odds ratio 8.3, 95% confidence interval 1.5 to 46.6), and tocolysis (odds ratio 4.1, 95% confidence interval 1.0 to 16.0) were associated with birth within 7 days; fetal fibronectin (odds ratio 3.6, 95% confidence interval 2.2 to 5.9), prior preterm birth (odds ratio 2.5, 95% confidence interval 1.4 to 4.4), cervical dilatation >1 cm (odds ratio 2.9, 95% confidence interval 1.6 to 5.2), and tocolysis (odds ratio 4.5, 95% confidence interval 2.8 to 7.2) were all independently associated with delivery before 37 weeks. CONCLUSION: In a population of patients with symptoms, the presence of fetal fibronectin in vaginal secretions best defines a subgroup at increased risk for delivery within 7 days; the high negative predictive value of fetal fibronectin sampling supports less intervention for patients with this result.(Am J Obstet Gynecol 1997;177:13-8)

Le texte complet de cet article est disponible en PDF.

Keywords : Fetal fibronectin, preterm birth, prematurity


Plan


 From the Departments of Obstetrics and Gynecology, Northwestern University, University of Alabama at Birmingham, University of North Carolina, Ohio State University, Hennepin County Medical Center, University of Texas at Houston, Stanford University, Good Samaritan Hospital (Phoenix), Hartford Hospital, and University of Louisville.
☆☆ Funding from Adeza Biomedical.
 Reprints not available from the authors.
★★ 6/1/81721


© 1997  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 177 - N° 1

P. 13-18 - juillet 1997 Retour au numéro
Article précédent Article précédent
  • The preterm prediction study: Patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery
  • Robert L. Goldenberg, Brian M. Mercer, Jay D. Iams, Atef H. Moawad, Paul J. Meis, Anita Das, Donald McNellis, Menachem Miodovnik, M.Kathryn Menard, Steve N. Caritis, Gary R. Thurnau, Sidney F. Bottoms, The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network
| Article suivant Article suivant
  • Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1?, and tumor necrosis factor-?), neonatal brain white matter lesions, and cerebral palsy
  • Bo Hyun Yoon, Jong Kwan Jun, Roberto Romero, Kyo Hoon Park, Ricardo Gomez, Jung-Hwan Choi, In-One Kim

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.